3 Biotech

, 9:178 | Cite as

Differential expression of Helios, Neuropilin-1 and FoxP3 in head and neck squamous cell carcinoma (HNSCC) patients

  • A. A. Mohamed Adil
  • Anil Kumar Bommanabonia
  • Anandraj Vaithy
  • Sateesh Kumar
  • Mohammad Waseem
  • Shazia Jamal
  • Neesar AhmedEmail author
Original Article


In recent years, studies have begun to explore the immune involvement in head and neck tumors. Advanced stage head and neck squamous cell carcinoma (HNSCC) has a poor prognosis with low survival rates with high level of immune infiltrates. Tregs (regulatory T cells) play a crucial role in constructing an immunosuppressive tumor microenvironment. In the present study, we highlighted specific Treg markers and its factors in HNSCC solid tumors and peripheral blood of cancer patients. By histopathology and immunofluorescence staining, we observed differential expression of CD4, CD25, Foxp3, Helios and Neuropilin-1. Further, we analyzed the expression of Foxp3, Helios, Neuropilin-1 and GARP by qPCR and flow cytometry in whole blood and found to be elevated in HNSCC patients in comparison with healthy donors. Additionally, IFN-γ, TGF-β, IL-6, IL-2, IL-10 and TNF-α expressions were also found to be relatively increased in the head and neck cancer patients when compared with healthy donors. Our findings emphasize that Tregs may be involved in promoting tumor progression. Helios and Neuropilin-1 could be potent markers in identifying subsets of Tregs. Association of soluble factors could sculpture the activity of Tregs. With further research, Treg markers and its associated soluble factors could be employed to block Tregs trafficking to the tumor, thus enlightening a potential strategy for targeting human cancers.


Squamous cell carcinoma HNSCCs Tregs Foxp3 CD4 Soluble factors 



We would like to thank DST-SERB (No: YSS/2014/000424) Govt. of INDIA and the first author thanks the Maulana Azad national fellowship scheme (UGC) (F1-17.1/2014-15/MANF-2014-15-MUS-PON-44115).

Compliance with ethical standards

Conflict of interest

The authors have no conflicts of interest to declare.


  1. Aggarwal S, Sharma SC, Das SN (2017) Dynamics of regulatory T cells (Tregs) in patients with oral squamous cell carcinoma. J Surg Oncol 116:1103–1113. CrossRefPubMedGoogle Scholar
  2. Barnes TA, Amir E (2017) HYPE or HOPE: the prognostic value of infiltrating immune cells in cancer. Br J Cancer 117:451. CrossRefPubMedPubMedCentralGoogle Scholar
  3. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians 68:394-424. doi:10.3322/caac.21492Google Scholar
  4. Chinen T et al (2016) An essential role for the IL-2 receptor in Treg cell function. Nat Immunol 17:1322–1333. CrossRefPubMedPubMedCentralGoogle Scholar
  5. Drennan S, Stafford ND, Greenman J, Green VL (2013) Increased frequency and suppressive activity of CD127(low/−) regulatory T cells in the peripheral circulation of patients with head and neck squamous cell carcinoma are associated with advanced stage and nodal involvement. Immunology 140:335–343. CrossRefPubMedPubMedCentralGoogle Scholar
  6. Elkord E, Abd Al Samid M, Chaudhary B (2015) Helios, and not FoxP3, is the marker of activated Tregs expressing GARP/LAP. Oncotarget 6:20026–20036PubMedPubMedCentralGoogle Scholar
  7. Fujimoto M et al (2011) The influence of excessive IL-6 production in vivo on the development and function of Foxp3+ regulatory T cells. J Immunol 186:32–40. CrossRefPubMedGoogle Scholar
  8. Graziani G, Lacal PM (2015) Neuropilin-1 as therapeutic target for malignant melanoma. Front Oncol 5:125. CrossRefPubMedPubMedCentralGoogle Scholar
  9. Grzanka J et al (2013) FoxP3, Helios, and SATB1: roles and relationships in regulatory T cells. Int Immunopharmacol 16:343–347. CrossRefPubMedGoogle Scholar
  10. Hadrup S, Donia M, thor Straten P, (2013) Effector CD4 and CD8 T cells and their role in the tumor microenvironment. Cancer Microenviron 6:123–133. CrossRefPubMedGoogle Scholar
  11. Jie H-B et al (2015) CTLA-4(+) Regulatory T cells increased in cetuximab treated head and neck cancer patients suppress NK cell cytotoxicity and correlate with poor prognosis. Cancer Res 75:2200–2210. CrossRefPubMedPubMedCentralGoogle Scholar
  12. Jin H, Sun L, Tang L, Yu W, Li H (2017) Expression of GARP is increased in tumor-infiltrating regulatory T cells and is correlated to clinicopathology of lung cancer patients. Front Immunol 8:138. CrossRefPubMedPubMedCentralGoogle Scholar
  13. Jubb AM, Strickland LA, Liu SD, Mak J, Schmidt M, Koeppen H (2012) Neuropilin-1 expression in cancer and development. J Pathol 226:50–60. CrossRefPubMedGoogle Scholar
  14. Karagöz B et al. (2010) CD8+CD28- cells and CD4+CD25+ regulatory T cells in the peripheral blood of advanced stage lung cancer patients Med Oncol 27:29-33 doi:10.1007/s12032-008-9165-9Google Scholar
  15. Kulkarni MR (2018) Head and neck cancer burden in india. Int J Head Neck Surg 10:10001–11132Google Scholar
  16. Lee W, Lee GR (2018) Transcriptional regulation and development of regulatory T cells. Exp Mol Med 50:e456. CrossRefPubMedPubMedCentralGoogle Scholar
  17. Li MO, Rudensky AY (2016) T cell receptor signaling in the control of regulatory T cell differentiation and function. Nat Rev Immunol 16:220–233. CrossRefPubMedPubMedCentralGoogle Scholar
  18. Melero I, Sznol M, Tessmer MS, Whiteside TL, Wolchok JD (2018) Introducing a new series: immunotherapy facts and hopes. Clin Cancer Res 24:1773–1774. CrossRefPubMedGoogle Scholar
  19. Mihm MC, Mulé JJ (2015) Reflections on the histopathology of tumor-infiltrating lymphocytes in melanoma and the host immune response cancer. Immunol Res 3:827–835. CrossRefGoogle Scholar
  20. Mohamed Adil AA, Jamal S, Ahmed V (2014) Cancer immunotherapy: targeting immunosuppressive tumor microenvironment Oncobiology and Targets. Oncobiol Targets 1(27):1236Google Scholar
  21. Mohamed Adil AA, Anandraj V, Kumar S, Waseem M, Chitra K, Kumar BA, Jamal S, Ahmed N (2018) Role of mesenchymal cells and immunosuppressive cells within inflammatory tumor microenvironment. J Hematol Oncol Forcast 1:1005Google Scholar
  22. Moon B-I, Kim TH, Seoh J-Y (2015) Functional modulation of regulatory T cells by IL-2. PLOS ONE 10:e0141864. CrossRefPubMedPubMedCentralGoogle Scholar
  23. Moskovitz J, Moy J, Ferris RL (2018) Immunotherapy for head and neck squamous cell carcinoma. Curr Oncol Rep 20:22. CrossRefPubMedPubMedCentralGoogle Scholar
  24. Phé V, Rouprêt M, Cussenot O, Chartier-Kastler E, Gamé X, Compérat E (2015) Forkhead box protein P3 (Foxp3) expression serves as an early chronic inflammation marker of squamous cell differentiation and aggressive pathology of urothelial carcinomas in neurological patients. BJU Int 115:28–32. CrossRefPubMedGoogle Scholar
  25. Poddar A, Aranha RR, Muthukaliannan K, G, Nachimuthu R, Jayaraj R, (2018) Head and neck cancer risk factors in India: protocol for systematic review and meta-analysis. BMJ Open 8:e020014–e020014. CrossRefPubMedPubMedCentralGoogle Scholar
  26. Pourgholaminejad A, Aghdami N, Baharvand H, Moazzeni SM (2016) Is TGFβ as an anti-inflammatory cytokine required for differentiation of inflammatory TH17 cells? J Immunotoxicol 13:775–783. CrossRefPubMedGoogle Scholar
  27. Ramsdell F, Ziegler SF (2014) FOXP3 and scurfy: how it all began. Nat Rev Immunol 14:343–349. CrossRefPubMedGoogle Scholar
  28. Sebastian M, Lopez-Ocasio M, Metidji A, Rieder SA, Shevach EM, Thornton AM (2016) Helios controls a limited subset of regulatory T cell functions. J Immunol 196:144–155. CrossRefPubMedGoogle Scholar
  29. Shitara K, Nishikawa H (2018) Regulatory T cells: a potential target in cancer immunotherapy. Ann NY Acad Sci 1417:104–115. CrossRefPubMedGoogle Scholar
  30. Sidaway P (2017) Neuropilin-1 is required for Treg stability. Nat Rev Clin Oncol 14:458. CrossRefPubMedGoogle Scholar
  31. Singh K, Hjort M, Thorvaldson L, Sandler S (2015) Concomitant analysis of Helios and Neuropilin-1 as a marker to detect thymic derived regulatory T cells in naïve mice. Sci Rep 5:7767. CrossRefPubMedPubMedCentralGoogle Scholar
  32. Sun L, Jin H, Li H (2016) GARP: a surface molecule of regulatory T cells that is involved in the regulatory function and TGF-β releasing. Oncotarget 7:42826–42836. CrossRefPubMedPubMedCentralGoogle Scholar
  33. Szurek E, Cebula A, Wojciech L, Pietrzak M, Rempala G, Kisielow P, Ignatowicz L (2015) Differences in expression level of Helios and Neuropilin-1 do not distinguish thymus-derived from extrathymically-induced CD4+Foxp3+ regulatory T cells. PLOS ONE 10:e0141161. CrossRefPubMedPubMedCentralGoogle Scholar
  34. Takatori H et al (2015) Helios enhances treg cell function in cooperation with FoxP3. Arthritis Rheumatol 67:1491–1502. CrossRefPubMedGoogle Scholar
  35. Thornton AM, Korty PE, Kim YC, Martens C, Shevach EM (2018) Helios expression defines a phenotypically distinct population of Treg cells. J Immunol 200:116119–116119Google Scholar
  36. Tokuno K, Hazama S, Yoshino S, Yoshida S, Oka M (2009) Increased prevalence of regulatory T-cells in the peripheral blood of patients with gastrointestinal cancer. Anticancer Res 29:1527–1532PubMedGoogle Scholar
  37. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics. CA A Cancer J Clin 65:87–108. CrossRefGoogle Scholar
  38. Tu E, Chia PZC, Chen W (2014) TGFβ in T cell biology and tumor immunity: angel or devil? Cytokine Growth Factor Rev 25:423–435. CrossRefPubMedPubMedCentralGoogle Scholar
  39. Tu J-F et al (2016) Regulatory T cells, especially ICOS+ FOXP3+ regulatory T cells, are increased in the hepatocellular carcinoma microenvironment and predict reduced survival. Sci Rep 6:35056. CrossRefPubMedPubMedCentralGoogle Scholar
  40. Ward-Hartstonge KA, Kemp RA (2017) Regulatory T-cell heterogeneity and the cancer immune response. Clin Trans Immunol 6:e154. CrossRefGoogle Scholar
  41. Whiteside TL (2018a) FOXP3+ Treg as a therapeutic target for promoting anti-tumor immunity. Expert Opin Ther Targets 22:353–363. CrossRefPubMedPubMedCentralGoogle Scholar
  42. Whiteside TL (2018b) Head and neck carcinoma immunotherapy: facts and hopes. Clin Cancer Res 24:6–13. CrossRefPubMedGoogle Scholar
  43. Wolf D et al (2005) The expression of the regulatory T cell–specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res 11:8326–8331. CrossRefGoogle Scholar

Copyright information

© King Abdulaziz City for Science and Technology 2019

Authors and Affiliations

  1. 1.School of Life SciencesB S Abdur Rahman Crescent Institute of Science and TechnologyChennaiIndia
  2. 2.Diagnostic Research LaboratoryGorimeduIndia
  3. 3.Departmentof Oral Pathology and MicrobiologyIndira Gandhi Institute of Dental SciencesPillayarkuppamIndia
  4. 4.School of MedicineUniversity of AlabamaBirminghamUSA

Personalised recommendations